SGMO News and Press, Sangamo Therapeutics Inc. From 04/27/21

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 11-14, 2021, in a virtual format. “Our zinc finger tech...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2021 financial results after the market closes on Tuesday, May 4, 2021. The press release will be followed by a conference call at 5:00 ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in the virtual Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease conference on April 1, 2021. Sangamo management is expected to participate in a p...

Do You Have These Top Biotech Stocks On Your Watchlist? It goes without saying that the biotech sector remains a crucial aspect of the broader healthcare industry today. By extension, this would help explain why investors continue to watch the top biotech stocks . This would be ...

Sangamo Therapeutics (SGMO) announces that the European Medicines Agency’s Committee for Orphan Medicinal Products ((COMP)) released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cel...

Genomic medicine collaborations are a valuable method of risk mitigation. They also are a source of funding which can be used to build a deeper pipeline. Sangamo is leveraging many pharmaceutical leaders to help fund an emerging pipeline of owned programs. Cash flows from col...

Today, we revisit Sangamo Therapeutics, which is a nice sum of the parts story given multiple drug candidates and partnerships with several drug giants. The company recently gave a corporate update and posted fourth quarter results. We updated our investment thesis on Sangamo in t...

The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with this event. For further details see: Sangamo Therapeutics (SGMO) Presents At SVB Leerink 10th Annual Global Healthcare Conference - Slideshow

Image source: The Motley Fool. Sangamo Therapeutics Inc (NASDAQ: SGMO) Q4 2020 Earnings Call Feb 25, 2021 , 8:00 p.m. ET Operator Continue reading For further details see: Sangamo Therapeutics Inc (SGMO) Q4 2020 Earnings Call Transcript ...